



MAYNE PHARMA TO HOST INVESTOR DAY ON MAY 1ST, 2017 IN SYDNEY

26 April 2017, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that it will host an Investor Day on 1st May 2017 in Sydney. Mayne Pharma CEO Scott Richards and members of the global leadership team will provide an overview of the Company's growth strategy.

The presentation will be broadcast live via webcast beginning at 2pm AEST. The meeting is expected to conclude by 4.30pm AEST. In-person attendance is by invitation only.

To assess the live webcast and view the accompanying slide presentations, please visit the [Mayne Pharma](#) website or access the webcast link [here](#), at least 15 minutes before the presentation is scheduled to begin to register and install any necessary software. If you are unable to view the live webcast, a replay will be available after the event's conclusion.

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including highly potent compounds, controlled substances, modified-release products and inherently unstable compounds.